About Osmol Therapeutics
Osmol Therapeutics is a company based in New Haven (United States) founded in 2016 by Barbara Ehrlich.. Osmol Therapeutics has raised $7.5 million across 2 funding rounds from investors including Koax Investment Partners. Osmol Therapeutics offers products and services including OSM-0205. Osmol Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter New Haven, United States
- Founders Barbara Ehrlich
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Osmol Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.5 M (USD)
in 2 rounds
-
Latest Funding Round
$5.2 M (USD), Series A
Apr 12, 2022
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Osmol Therapeutics
Osmol Therapeutics offers a comprehensive portfolio of products and services, including OSM-0205. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Prevents CIPN and CICI in chemotherapy patients
Funding Insights of Osmol Therapeutics
Osmol Therapeutics has successfully raised a total of $7.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $5.2 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $5.2M
-
First Round
First Round
(28 Feb 2022)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2022 | Amount | Series A - Osmol Therapeutics | Valuation | Koax Investment Partners |
|
| Feb, 2022 | Amount | Seed - Osmol Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Osmol Therapeutics
Osmol Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Koax Investment Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Osmol Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Osmol Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Osmol Therapeutics Comparisons
Competitors of Osmol Therapeutics
Osmol Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Osmol Therapeutics
When was Osmol Therapeutics founded?
Osmol Therapeutics was founded in 2016 and raised its 1st funding round 6 years after it was founded.
Where is Osmol Therapeutics located?
Osmol Therapeutics is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Who is the current CEO of Osmol Therapeutics?
Bob Linke is the current CEO of Osmol Therapeutics.
Is Osmol Therapeutics a funded company?
Osmol Therapeutics is a funded company, having raised a total of $7.5M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2.3M, raised on Feb 28, 2022.
What does Osmol Therapeutics do?
Osmol Therapeutics was founded in 2016 in New Haven, United States, focusing on biotechnology for oncology support. Treatments targeting chemotherapy-induced peripheral neuropathy (CIPN) are developed, with the lead candidate OSM-0205 designed to modulate intracellular calcium through a novel mechanism. This approach aims at preventing CIPN in breast cancer patients receiving taxane-based therapies, addressing a key side effect in cancer care.
Who are the top competitors of Osmol Therapeutics?
Osmol Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
What products or services does Osmol Therapeutics offer?
Osmol Therapeutics offers OSM-0205.
Who are Osmol Therapeutics's investors?
Osmol Therapeutics has 1 investor. Key investors include Koax Investment Partners.